ABUS
Arbutus Biopharma Corporation
Biotechnology · Healthcare · United States
4.28
close · 2026-10-29
value
74
cheaper than peers74
quality
100
stronger fundamentals100
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.73× | 77 |
| EV to EBITDA | 5.36× | 72 |
| price to book | 3.27× | 52 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 94.4% | 100 |
| revenue growth | 10054.5% | 98 |
| return on equity | 94.7% | 97 |
| debt to equity | 1.5% | 89 |
4 of 4 measures available
Facts
| market cap | $656M |
| free cash flow | -$90.4M |
| employees | 19 |
| first trade | 2007-07-26 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.17 | -0.38 | -0.44 | -0.46 |
| free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M |
| net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M |
| revenue | $14.1M | $6.2M | $18.1M | $39.0M |
| unusual items | -$10.4M | -$6.4M | -$44,000 | -$2.3M |